Company Profile

Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the bodyâ€™s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.

Employees

Sector

Investment Holding Companies

More about the company

24-12-15	Histogen Inc. Went Out of Business	CI
24-12-01	Modified First Amended Liquidation Plan Approved for Histogen Inc.	CI
24-09-30	First Amended Liquidation Plan Filed by Histogen Inc.	CI
24-08-30	Bankruptcy Judge Changed for Histogen Inc.	CI
24-07-14	Liquidation Plan Filed by Histogen Inc.	CI
24-04-19	Subchapter V Trustee Appointed Under Chapter 11 for Histogen Inc.	CI
24-04-18	Histogen Inc. Filed for Bankruptcy	CI
23-11-09	Histogen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-10-04	Histogen Inc.(OTCPK:HSTO) dropped from NASDAQ Composite Index	CI
23-10-03	Histogen Inc. and Allergan Mutually Elect to Terminate the Amended and Restated License Agreement	CI
23-09-22	Histogen Inc.(NasdaqCM:HSTO) dropped from S&P TMI Index	CI
23-09-20	Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates	MT
23-09-20	Top Premarket Gainers	MT

22-03-29	HC Wainwright Adjusts Histogen's Price Target to $1.50 From $2.40, Reiterates Buy Rating	MT
21-08-30	HISTOGEN : HC Wainwright Starts Histogen at Buy With $2.40 Price Target	MT
21-06-04	HISTOGEN : Canaccord Genuity Adjusts Histogen PT to $4 From $5, Maintains Buy Rating	MT
21-06-04	HISTOGEN : Canaccord Genuity Adjusts Histogen's Price Target to $4 From $5, Reiterates Buy Rating	MT
21-03-04	HISTOGEN : Canaccord Genuity Initiates Coverage on Histogen at Buy Rating, Sets Price Target at $5	MT

24-04-18	Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering	AQ
23-12-14	Histogen Announces Second Adjournment of Special Meeting of Stockholders	AQ
23-12-05	Histogen Announces Adjournment of Special Meeting of Stockholders	AQ
23-11-10	Histogen: Q3 Earnings Snapshot	AQ
23-09-18	Histogen Announces Board Approval of Complete Liquidation and Dissolution	AQ

23-07-06	MÄRKTE USA/Schwächer - Robuste Wirtschaftsdaten treiben Zinsen nach oben
23-07-06	MÄRKTE USA/Stark steigende Zinsen schicken Aktien auf Talfahrt
23-07-06	MÄRKTE USA/Schwach - Robuster US-Arbeitsmarkt befeuert Zinssorgen
23-07-06	MÄRKTE USA/Zinssorgen dürften drücken - ADP-Daten belasten Renten
23-04-04	MÄRKTE USA/Wall Street mit leichten Aufschlägen

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-06-19	Brian Satz	Free	Director	6,835	0.1600%
23-06-19	Susan Windham-Bannister	Free	Director	6,835	0.1600%
23-06-19	David Crean	Free	Chairman	6,835	0.1600%

Histogen Inc. Stock

Stocks

HSTO.Q

US43358Y2028

Investment Holding Companies

Chart: Histogen Inc.

Latest news : Histogen Inc.

Analysts' recommendations: Histogen Inc.

Press Releases: Histogen Inc.

News in other languages: Histogen Inc.

Quotes and Performance

Latest insider transactions

Shell Companies

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HISTOGEN INC.	+316.67%	+525.00%	-	-	5.34K
FACTORIAL ENERGY INC.	+1.44%	-9.96%	-	-	1.56B
EINRIDE AB	-10.92%	-20.05%	-	-	1.32B
AIR GLOBAL PLC	+1.88%	+0.43%	-	-	1.26B
CHURCHILL CAPITAL CORP VII	-0.30%	-.--%	-.--%	-2.77%	915M
CENTIEL AG	-2.01%	+16.42%	+385.07%	-61.00%	819M
PRIME BEING CORP.	-35.29%	-35.29%	+44.74%	+391.07%	797M
ACC AVIATION HOLDINGS LTD.	+42.00%	0.00%	+1,320.00%	+343.75%	709M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	0.00%	+0.20%	-	-	643M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	-.--%	-.--%	-.--%	600M
Average	+31.35%	+2.16%	+349.96%	+134.21%	958.52M
Weighted average by Cap.	-1.17%	+0.43%	+335.04%	+130.94%